Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
| Study title | Condition | Phase | Location | |
|---|---|---|---|---|
|
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases |
Myeloid Diseases | Phase1 |
France Germany Hong Kong Italy Singapore Spain United States View All
|
NCT05552469 |
|
Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer |
Non-small Cell Lung Cancer | Phase1 |
Germany Japan Korea, Republic of Spain Switzerland United States View All
|
NCT05275868 |
|
Ribociclib (LEE011) Rollover Study for Continued Access |
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies | Phase2 |
Taiwan United States |
NCT02934568 |
|
Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study |
Multiple Sclerosis | Switzerland | NCT05285904 | |
|
A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis |
Relapsing Multiple Sclerosis | Germany | NCT05344469 | |
|
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease |
Steroid-refractory Acute Graft Versus Host Disease | Phase4 | China | NCT06462469 |
|
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors |
Mesothelioma | Phase1 |
Australia Canada France Germany Italy Japan Netherlands Spain Switzerland United Kingdom United States View All
|
NCT04857372 |
|
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis |
Multiple Sclerosis (MS) | Phase3 |
Argentina Australia Austria Belgium Brazil Canada Chile Croatia Estonia France Germany Guatemala India Israel Italy Latvia Mexico Poland Portugal Romania Serbia Slovakia Spain Taiwan Turkey United States View All
|
NCT04926818 |
|
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus |
Systemic Lupus Erythematosus, Lupus Nephritis | Phase1, Phase2 |
Australia France Germany Spain Switzerland United States View All
|
NCT05798117 |
|
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer |
Prostate Cancer | Phase4 |
Austria Belgium Canada Czechia France Germany Netherlands Spain Sweden United Kingdom United States View All
|
NCT05803941 |